NEW YORK, NY / ACCESSWIRE / July 6, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
PCT Shareholders Click Here: https://www.zlk.com/pslra-1/purecycle-technologies-inc-information-request-form?prid=17440&wire=1
SKLZ Shareholders Click Here: https://www.zlk.com/pslra-1/skillz-inc-f-k-a-flying-eagle-acquisition-corp-loss-submission-form?prid=17440&wire=1
ATHA Shareholders Click Here: https://www.zlk.com/pslra-1/athira-pharma-inc-loss-submission-form?prid=17440&wire=1
* ADDITIONAL INFORMATION BELOW *
PureCycle Technologies, Inc. (NASDAQ:PCT)
PCT Lawsuit on behalf of: investors who purchased November 16, 2020 - May 5, 2021
Lead Plaintiff Deadline: July 12, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/purecycle-technologies-inc-information-request-form?prid=17440&wire=1
According to the filed complaint, during the class period, PureCycle Technologies, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the technology PureCycle licensed from Procter & Gamble is not proven and presents serious issues even at lab scale; (ii) the challenges posed by the availability and competition for the raw materials necessary to commercialize the licensed technology are significant; (iii) PureCycle's financial projections are baseless; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Skillz Inc. f/k/a Flying Eagle Acquisition Corp. (NYSE:SKLZ)
SKLZ Lawsuit on behalf of: investors who purchased December 16, 2020 - April 19, 2021
Lead Plaintiff Deadline: July 7, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/skillz-inc-f-k-a-flying-eagle-acquisition-corp-loss-submission-form?prid=17440&wire=1
According to the filed complaint, during the class period, Skillz Inc. f/k/a Flying Eagle Acquisition Corp. made materially false and/or misleading statements and/or failed to disclose that: representations relating to certain of Skillz's business operations, performance metrics and ultimate valuation, including, among others, Skillz's ability to attract new end-users, future profitability, the shrinking popularity of its hosted games that accounted for 88% of its revenue, and the Company's valuation. For example, one of the Company's objectively unrealistic promises included the unsupportable claim that the Company was valued at $3.5 billon, based on revenue projections in excess of $550 million for 2022. However, the Company failed to inform investors that downloads of the games that account for a majority share of its revenue have been declining since at least November 2020. In reality, the Company's prospects for attaining that revenue scale was far from realistic given its size, market share, reliance on thirdparty app stores, declining downloads of its most popular games and, critically, the enormous amount of incentive Bonus Payments that Skillz routinely provides to its gamer customers, a fact that investors were misled about. These Bonus Payments are routinely provided to its customers, who are expected to use them for game entry fees, which, in turn, artificially inflates Skillz revenue.
Athira Pharma, Inc. (NASDAQ:ATHA)
This lawsuit is on behalf of investors who purchased Athira Pharma, Inc. (NASDAQ:ATHA) between September 18, 2020 and June 17, 2021 and/or purchased common stock in or traceable to the Company's registration statement issued in connection with the Company's September 2020 initial public offering priced at $17.00 per share.
Lead Plaintiff Deadline: August 24, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/athira-pharma-inc-loss-submission-form?prid=17440&wire=1
According to the filed complaint, (1) the research conducted by Defendant Kawas, which formed the foundation for Athira's product candidates and intellectual property, was tainted by Kawas' scientific misconduct, including the manipulation of key data through the altering of Western blot images; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and omitted material facts necessary in order to make the statements made not misleading.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP